NASDAQ : BDTX

Black Diamond Therapeutics, Inc.

$1.855 USD

$0.04 (2.49%)

Volume
119.74K
Average Volume
1.77M
Market Capitalization
$106.29M
P/E Ratio
-2.44
Dividend Yield
0.00%
Price Target
$9.50
Year High
$4.94
Year Low
$1.60
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$8.46
Company Overview

NASDAQ

Mark A. Velleca

Biotechnology

Healthcare

BDTX

21

US

USD

https://www.blackdiamondtherapeutics.com

617 252 0848

09203E105

0001701541

Liquidity Metrics

0.17

8.46

8.46

2.07

0.00

Sales & Valuation

$70M

0.00

1.02

-3.12

-0.59

Profitability

$0.39

$22.37M

0.00%

0.00%

-36.37%

-32.51%

P/E Metrics

-2.44

0.00

0.00

Analyst Price Target & Rating

$9.50

$20.00

$8.00

Neutral

3/5

11 Analysts

-80.47%

Poll Results

About Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Stock

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class ... I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.

Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside

2026-07-06 01:51:02

Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.

BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst

2026-05-27 12:21:12

Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.

Black Diamond Stock Outlook After Q1 Beat and Cash Runway

2026-05-27 12:15:43

BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.

BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know

2026-05-27 12:11:08

Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.

What's Going On With Black Diamond Therapeutics Stock Tuesday?

2026-05-26 11:31:12

Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.

BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data

2026-05-25 11:55:30

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

2026-05-22 08:00:00

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

2026-05-21 19:09:20

Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.

Frequently Asked Questions

What is the current Black Diamond Therapeutics, Inc. (BDTX) stock price?

Black Diamond Therapeutics, Inc.(NASDAQ:BDTX) stock price is $1.855 in the last trading session. During the trading session, BDTX stock reached the peak price of $4.94 while $1.6 was the lowest point it dropped to. The percentage change in BDTX stock occurred in the recent session was 2.49% while the dollar amount for the price change in BDTX stock was $0.04.

BDTX's industry and sector of operation?

The NASDAQ listed BDTX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BDTX?

Brent Hatzis-Schoch | Chief Operating Officer & General Counsel
Elizabeth Buck | Co-Founder & Chief Scientific Officer
Mark A. Velleca | Chief Executive Officer, President & Chairman
Erika Jones | Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
Melanie Morrison | Chief Development Officer

How many employees does BDTX have?

Number of BDTX employees currently stands at 21. BDTX operates from 245 First Street, Cambridge, MA 02142, US.

Link for BDTX official website?

Official Website of BDTX is: https://www.blackdiamondtherapeutics.com

How do I contact BDTX?

BDTX could be contacted at phone #617 252 0848 and can also be accessed through its website. BDTX operates from 245 First Street, Cambridge, MA 02142, US.

How many shares of BDTX are traded daily?

The average number of BDTX shares traded daily for last 3 months was 1.77M.

What is the market cap of BDTX currently?

The market value of BDTX currently stands at $106.29M with its latest stock price at $1.855